BIO-TECHNE Corp reported revenue of $0.32B for the period ended 2026-06-30, +1.3% year on year. Net income was $0.05B, a 17.0% net margin on a 65.8% gross margin. Free cash flow for the period was $0.18B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $0.32B | +1.3% |
| Gross profit | $0.21B | — |
| Operating income | $0.07B | — |
| Net income | $0.05B | +409.0% |
| Gross margin | 65.8% | Net margin 17.0% |
| Revenue Q/Q | +3.1% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.11B | 34.2% |
| R&D | $0.02B | 7.5% |
| SG&A | $0.11B | 35.2% |
| Tax & other | $0.02B | 6.1% |
| Item | Amount |
|---|---|
| Total assets | $2.55B |
| Total liabilities | $0.47B |
| Shareholders' equity | $2.09B |
| Equity / assets | 81.8% |
| Operating cash flow | $0.20B |
| Capital expenditure | $0.02B |
| Free cash flow | $0.18B |
| Cash conversion (OCF / net income) | 170% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
BIIB ・ BLK ・ BX ・ XYZ ・ BNY ・ BA ・ BKNG ・ BSX ・ BMY ・ AVGO ・ BR ・ BRO
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies